FLGT (34) BDSX (44) TLSI (34) XGN (31) ⌘ Pro Terminal →

YD Bio Limited (YDES) — RQD Stock Rating Cockpit

$5.87 -6.53% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.79

YD Bio Limited (YDES) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $415.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.79 (-1.37%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for YDES)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (37/100 Composite)

🔍 WHY YDES SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (38% of score)

Altman Z-Score 13.44 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 16.7% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$6.73-12% Next Q

Q2 (-2Q)

Grade D$5.92-16.4% Next Q

Q3 (-1Q)

Grade D$4.95+18.6% Next Q

Current

Grade D-$5.87-8.1% Hist 90D α

Trajectory: D (45) → D- (37)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a YDES Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While YDES currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.12) and Max Pain ($6.16) forces dealer call-delta covering toward $16.51.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $YDES• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “YDES Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 37%NO 63%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

52.330 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

13.44>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

4 / 99-Pt Accounting

52-WEEK LASER RANGE30% OF RANGE

L: $2$5.87H: $16

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 9 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on YDES

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (40)

-20.0% ROIC with 28.1% gross margin and -1.93% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (70)

Altman-Z 13.44 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (25)

9/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like YDES

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring YDES)

✓Walkthrough of YDES's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

YDES // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +15.10%▲ ASCENDING CHANNEL

2026-10-30O $5.99H $6.10L $5.67C $5.87VOL 47.3K

RES: $9.02SUP: $2.76SMA50: $5.12SMA200: $5.52

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

YDES Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 YDES Butterfly Map → + Track YDES →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +16.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on YDES today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for YDES. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for YDES today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (YDES)

Health Care Rank #748 of 1016 ⚔️ FLGT vs YDES Full Matrix →

1. Head-to-Head Health Care Peer Comparison (YDES vs. FLGT, BDSX, TLSI, XGN)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, YD Bio Limited (YDES) ranks #748 by composite RQD confidence (37/100, grade D-) and #477 by equity capitalization ($415.8M). Within this direct 5-issuer industry benchmark cohort, YDES leads on earnings valuation at N/A trailing P/E, while FLGT leads on capital efficiency and profitability with -6.8% ROIC and 40.6% gross margin. BDSX currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with YDES at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
YDES ACTIVE YD Bio Limited	D-	37/100	—	28.1%	-20.0%	-6.53%	$415.8M	Benchmark Subject
FLGT Fulgent Genetics Inc.	E	34/100	—	40.6%	-6.8%	+0.74%	$596.5M	/flgt-vs-ydes →
BDSX Biodesix Inc.	D	44/100	—	—	-35.0%	+8.14%	$260.8M	/bdsx-vs-ydes →
TLSI TriSalus Life Sciences Inc.	E	34/100	—	84.6%	-35.0%	-1.78%	$237.7M	/tlsi-vs-ydes →
XGN Exagen Inc.	E	31/100	—	58.3%	-35.0%	+3.57%	$210.8M	/xgn-vs-ydes →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002011674

In its most recent audited fiscal period (FY2025, filed 2025-12-31), YD Bio Limited (YDES) reported GAAP revenue of $596.8K (+16.9% vs. FY2024 revenue of $510.4K , and +70.5% cumulative change since FY2023) , GAAP net income of -$8.3M, operating cash flow of -$6.6M, and free cash flow of -$8.0M (-519.4% YoY). On the balance sheet, YDES closed FY2025 with $13.8M in total assets against $0 in total debt (Altman Z-Score: 13.44, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$596.8K	-$8.3M	-$6.6M	-$8.0M	$13.8M	—
FY2024 (FY)	2024-12-31	$510.4K	-$1.4M	-$1.2M	-$1.3M	$6.9M	—
FY2023 (FY)	2023-12-31	$350.1K	$13.6K	-$55.7K	-$55.7K	—	—

3. YDES Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is YDES stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, YD Bio Limited (NASDAQ: YDES) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $5.87 (-6.53% 1D, market cap $415.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, YDES ranks #748 in composite RQD confidence.

How does YDES compare to FLGT and BDSX in the Health Care sector?

Within the Health Care sector (Medical Specialities), YDES carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of 28.1%, and ROIC of -20.0%. By comparison, FLGT (Fulgent Genetics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -6.8%, cap $596.5M) and BDSX (Biodesix Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $260.8M). Among the 5-stock peer group, YDES leads on earnings multiple (N/A) while FLGT leads on capital efficiency (-6.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for YDES?

Per YDES's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002011674), YD Bio Limited generated $596.8K in revenue (+16.9% YoY), -$8.3M in net income, and -$8.0M in free cash flow against $13.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is YDES trading relative to its 50-day, 200-day, and 52-week technical levels?

YDES last traded at $5.87 (-6.53% on volume of 96,187 shares), positioning the stock +14.65% above its 50-day simple moving average ($5.12) and +6.34% above its 200-day simple moving average ($5.52). Across its 52-week range of $1.70 to $15.72, YDES sits at the 29.7% percentile with a 14-day RSI of 52.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.14 to $6.60).

YDES Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell YDES stock right now?

YD Bio Limited (YDES) currently earns a Roarable Rating of D- (Sell — SELL) with 37/100 RQD Confidence. Stretched risk/reward at current multiples (-20% return on capital) under elevated 10-year interest-rate pressure.

What is YDES's 12-month price target and RQD AI Jury consensus?

YDES's 12-month base price target is $5.32 (range $4.15 to $16.51), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: YDES RQD Cockpit YDES 12M Forecast YDES Earnings & Move YDES Dividends & DRIP YDES Insiders & 13F YDES Whale Options YDES Profit Sankey YDES News & Why